Cullinan Therapeutics, INC 8-K filings

Cullinan Therapeutics announced its second quarter 2026 financial results, highlighting progress in its T cell engager programs for autoimmune diseases and cancer, alongside a robust cash position extending runway into 2029.

Cullinan Therapeutics stockholders re-elected two directors, ratified KPMG LLP as auditors, and approved executive compensation.

Cullinan Therapeutics announced updated clinical data for CLN-978 in rheumatoid arthritis and lupus, showing potential for remission, and initial data for velinotamig in lupus nephritis, demonstrating complete renal responses.

Cullinan Therapeutics announced initial clinical data from its Phase 1 OUTRACE trials for CLN-978, showing clinical benefit and B cell depletion in patients with rheumatoid arthritis and systemic lupus erythematosus.

Cullinan Therapeutics announced promising initial Phase 1 clinical data for its CD19xCD3 T cell engager, CLN-978, in patients with refractory rheumatoid arthritis and systemic lupus erythematosus.

Cullinan Therapeutics announced Q1 2026 financial results, highlighting FDA acceptance of the zipalertinib NDA and upcoming clinical data presentations for CLN-978.

Cullinan Therapeutics announced preliminary cash of $439 million, extending its runway into 2029, alongside significant clinical progress and upcoming data readouts for its immunology and oncology programs.

Cullinan Therapeutics presented updated positive Phase 1 clinical data for CLN-049 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome at the 67th ASH Annual Meeting.

Cullinan Therapeutics announced the termination of its exclusive license agreement with MIT for CLN-617, ceasing further development of the cancer immunotherapy.

Cullinan Therapeutics announced Q3 2025 financial results, a strategic pipeline focus, and an extended cash runway into 2029.

Cullinan Therapeutics announced new positive Phase 1 clinical data for CLN-049 in relapsed/refractory AML and MDS patients, to be presented at the ASH Annual Meeting.

Cullinan Therapeutics announced a delay in initial clinical data for its CLN-978 program in systemic lupus erythematosus to the first half of 2026, while other programs remain on track.

Cullinan Therapeutics announced its second quarter 2025 financial results, reporting an increased net loss while highlighting significant progress across its immunology and oncology clinical programs and strategic board appointments.

Cullinan Therapeutics, Inc. announced the successful passage of all four proposals at its Annual Meeting of Stockholders held on June 12, 2025, including the re-election of three Class II directors and the ratification of KPMG LLP as its independent accounting firm.

Cullinan Therapeutics has entered into an exclusive global licensing agreement with Genrix Bio for velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager, expanding its focus on autoimmune diseases while maintaining its cash runway into 2028.

Cullinan Therapeutics reports EMA approval for CLN-978, advancement of autoimmune and oncology programs, and a cash runway into 2028.

Cullinan Therapeutics reports positive Phase 2b results for zipalertinib and anticipates initial clinical data for CLN-978 in SLE in Q4 2025, with a cash runway into 2028.

Cullinan Therapeutics, in collaboration with Taiho Pharmaceutical, announced that the REZILIENT1 trial for zipalertinib in non-small cell lung cancer met its primary endpoint of overall response rate.

Cullinan Therapeutics reported progress across its clinical pipeline, including regulatory clearances for a lupus study and completed enrollment for a pivotal zipalertinib trial, alongside its third quarter 2024 financial results.

Cullinan Therapeutics has received FDA clearance for its Investigational New Drug application for CLN-978, a CD19 T cell engager, to begin a global Phase 1 clinical trial for systemic lupus erythematosus.

Cullinan Therapeutics has received ethics approval in Australia to begin a global Phase 1 clinical trial for its novel drug CLN-978, aimed at treating systemic lupus erythematosus (SLE).

Cullinan Therapeutics announced its second quarter 2024 financial results, highlighted by a strong cash position and progress in its clinical programs, including an upcoming IND filing for CLN-978.

Cullinan Therapeutics held its annual meeting on June 26, 2024, where stockholders elected two Class I directors and ratified the appointment of KPMG LLP as the independent accounting firm.

Cullinan Therapeutics reports positive initial Phase 2b trial data for zipalertinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations who progressed after amivantamab treatment.

Cullinan Therapeutics reports encouraging initial clinical results for CLN-619, both as a monotherapy and in combination with pembrolizumab, showing objective responses in various advanced solid tumors.

Cullinan Therapeutics reported its Q1 2024 financial results, announced a strategic shift to autoimmune diseases, and appointed a new board member.

Cullinan Therapeutics has announced the appointment of Mary Kay Fenton as its new Chief Financial Officer, effective immediately.

Cullinan Therapeutics has successfully completed a $280 million private placement and announced a strategic shift towards autoimmune disease therapies, particularly focusing on CLN-978 for systemic lupus erythematosus.

Cullinan Oncology announced its Q4 and full year 2023 financial results, provided a corporate update, and highlighted the departure of its CFO.